The use of a ligand for the B7 antigen for preparing a pharmaceutical composition useful for regulating CTLA4 positive T cell interactions with B7 positive cells, which ligand is capable of interfering with reaction of endogenous B7 antigen with CTLA4, wherein said ligand is a fusion protein that contains at least a portion of the extracellular domain of C